Back to Search Results- Unknown
- Diagnostic
- Interventional
- Randomized
- Drug
- EARLY_PHASE1
- BAMF Health
- 18 Years -
Study Purpose
Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
Intervention
Drug : illuccix 68Ga-PSMA-11 Total Body PET-CT
Eligibility Requirements
Provision of signed and dated informed consent form
Male ≥ 18 years of age
Patients meeting clinical need for Illuccix PET scan:
1. Patients with suspected metastasis who are candidates for initial definitive therapy
2. Patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
Patient is physically able to lay flat for the PET-CT procedure
Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.
Recruiting status
Unknown
Estimated enrollment
100
Study start date
Nov 01, 2022
Study end date
Dec 31, 2023
Last updated
Mar 24, 2025
Primary purpose
Diagnostic
Design
Interventional
Intervention
Drug
Study phase
EARLY_PHASE1
Allocation
Randomized
Sponsor:
BAMF Health
Collaborator:
Telix Pharmaceuticals (Innovations) Pty Limited
Investigator:
N/A
N/A
Publications
N/A
Websites
N/A
NCT05558956
| Clinic | Location | Investigator | Distance | RECRUITING STATUS | Contact |
|---|